Nautilus Biotech: "Next Generation Biopharmaceuticals (NGB)"
Paris. The Ministerial Conference of EUREKA, composed by a minister from each member country and a Commissioner from the European Commission announced the endorsement of the NGB project (E ! 3351) jointly presented by Nautilus Biotech (France) and Serono SA (Switzerland).
The NGB project associates Serono SA and Nautilus Biotech who will work together to develop next generation therapeutic proteins with improved biological, pharmacological and clinical profiles.
The partnership brings together a strong synergy between the two companies. Nautilus, which has proven proprietary technology for the improvement of bio-therapeutics, would design the new protein variants and validate them in vitro and in vivo. Serono would select protein variants created and validated by Nautilus and bring them through pre-clinical and clinical development to market.
"NGB is a strategic project for the two partners involved. It is expected to allow next generation therapeutic proteins, with improved profiles, to reach market and thus to improve patience compliance and quality of life," said Nautilus CEO Manuel Vega.
EUREKA is a pan-European network for market-oriented, industrial R&D. EUREKA supports the competitiveness of European companies through international collaboration, in creating links and networks of innovation. The objective is to bring high quality research and development efforts to the market and to use the multiplying effects of co-operation.
Using its proprietary technologies, Nautilus is strongly focused to improving human protein pharmaceuticals. Nautilus' pipeline is strategically focused on FDA-approved, marketed proteins, for which an improvement of their pharmacological profile would increase their already demonstrated clinical efficacy and market potential.
Additional information concerning Nautilus Biotech can be obtained from either www.nautilusbiotech.com or by e-mail: contact@nautilusbiotech.com .
Other news from the department science
